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Abstract 
To better understand the detection and management of iron overload in transfusion-dependent 
patients with myelodysplastic syndromes (MDS), a 15-minute web- or paper-based survey 
was conducted among 338 European physicians from 27 countries. Respondents had a mean 
of 18 years' clinical experience. 46% and 27% of physicians noted that detecting and treating 
iron overload were either ‘very important' or ‘important', respectively. The main reason for 
not actively exploring iron overload was related to poor patient prognosis, while the main 
reasons for not initiating iron chelation therapy were poor patient prognosis and older patient 
age. 37% and 31% of physicians believed that treating iron overload in these patients was 
‘very important' or ‘important', respectively. 90% of physicians prescribed iron chelation 
therapy, and 38% of transfusion-dependent patients received iron chelation therapy. The key 
reasons for not initiating iron chelation therapy related to poor patient prognosis (72%), 
patient age ≥85 years (50%) and comorbidities (34%). The views of these experienced MDS 
physicians reflect available international MDS treatment guidelines. 
 
Key words:  
MIDIS, Myelodysplastic syndromes, Transfusions, Iron overload, Iron chelation, Survey 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 3 
Introduction 
Red blood cell (RBC) transfusions are a common therapy to treat symptomatic anemia that 
affects most patients with myelodysplastic syndromes (MDS) [1]. Several retrospective 
studies have shown that patients who become RBC transfusion dependent have a significantly 
shorter overall survival than those who are not dependent on transfusions [2,3]. This 
decreased survival may in part be due to patients accumulating excess iron and/or to 
intrinsically more severe bone marrow disease than in non-dependent patients. International 
Prognostic Scoring System (IPSS) Low- and Intermediate-1 (Int-1)-risk patients, who may 
have prolonged survival, receive blood transfusions for many years and may be exposed to a 
greater risk of iron overload, leading to progressive dysfunction in organs such as the liver, 
heart and endocrine glands [2,4]. 
 
Guidelines from Spain, [5] The Italian Society of Hematology, [6] The UK MDS Guidelines 
Group, [7] The National Comprehensive Cancer Network in the USA [8] and The MDS 
Foundation [4] all recommend the use of iron chelation therapy in patients with Low- or Int-
1-risk MDS who have received more than 20 to 50 transfusions. In Europe, these 
recommendations, although not based on controlled clinical trials demonstrating superiority 
of iron chelation versus observation alone, have an impact on the perceptions and 
prescriptions of iron chelation therapy in patients with MDS. There is currently some 
controversy regarding the use of iron chelation therapy in these patients, particularly because 
they have a median age of 70 years, and many patients with a poor prognosis may not survive 
long enough to develop the clinical consequences of iron overload [9-11]. There is some 
argument, however, that even patients with higher-risk MDS may also benefit from iron 
chelation therapy through improved outcome of allogeneic stem cell transplantation, possible 
decreases in infection, and, although controversial, delayed leukemic transformation in some 
cases [6,12]. 
 
In order to understand what physicians treating transfusion-dependent patients with MDS in 
Europe believe to be the reasons for their willingness or reservations towards detecting and 
managing iron overload, a survey of European physicians has been conducted. The MDS 
Iron-overload Detection Insight Survey (MIDIS) was conducted by the MDS Foundation and 
the European School of Haematology (ESH) in partnership with Novartis Oncology. The 
results of the survey are presented here. 
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Design and Methods 
Inclusion/exclusion criteria 
To participate in the study, respondents had to be physicians from a European country, either 
fully qualified, in training or completing their internship, and seeing at least one transfusion-
dependent patient with MDS in an average 6-month period. 
 
MIDIS was initiated at the 2008 meeting of the American Society of Hematology and was 
also distributed at other international conferences via e-mails, letters and flyers, as well as 
links to the survey hosted on the MDS Foundation and ESH websites. 
 
Study questionnaire 
MIDIS was a quantitative survey that comprised up to 33 structured questions that could be 
completed either on paper or online in approximately 15 minutes. The questions were 
reviewed by a study steering committee, comprising the authors and external experts, prior to 
being included in the survey. The questions related to: profiling and demographics of the 
respondents (qualification status, primary specialty, work setting, number of transfusion-
dependent patients with MDS seen, involvement in MDS); detection of iron overload 
(frequency of serum ferritin testing, influence of serum ferritin tests on treatment decisions; 
importance of detecting iron overload, potential reasons for and reservations against 
detection); and treatment of iron overload with chelation therapy (importance of treatment, 
use of iron chelation therapy, markers for therapy initiation, number of patients who receive 
iron chelation therapy, potential reasons for and reservations against iron chelation therapy). 
Questions relating to detection and treatment of iron overload were answered using a scale 
from 1 (indicating not important at all) to 7 (very important). Questions relating to barriers 
and triggers for detecting and treating iron overload were also answered using a scale from 1 
(indicating not a barrier or trigger at all) to 7 (a strong barrier or trigger). 
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Analysis 
Collection and analysis of the MIDIS results were undertaken by the HealthCare Division of 
GfK SE. The results for both respondents’ background, and barriers and triggers toward 
detection and treatment of iron overload, were analyzed quantitatively. 
 
Results 
Respondent demographics 
A total of 338 physicians from 27 European countries participated in the survey (Table 1). 
Their profile shows that they were experienced clinicians specializing mostly in hematology 
(Table 2). A total of 88% were involved in diagnosing patients with MDS, 87% initiated 
treatment for MDS, and the same proportion was involved in the maintenance of treatment 
for MDS. The survey was completed by the respondents themselves. 
 
Table 1 Countries represented in the survey 
Country Responses Country Responses 
Austria 8 Macedonia 6 
Belgium 22 Malta 1 
Bulgaria 4 Netherlands 2 
Croatia 4 Norway 2 
Czech Republic 19 Poland 11 
Denmark 5 Portugal 9 
Estonia 4 Romania 6 
Finland 1 Serbia 1 
France 43 Slovakia 19 
Germany 20 Spain 45 
Greece 16 Sweden 4 
Hungary 3 Switzerland 7 
Italy 39 UK 36 
Lithuania 1   
Total number of responses  338 
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Table 2 Respondent characteristics 
Characteristic n = 338 
Mean age, years 44 
Male : female, n (%) 183 (54) : 155 (46) 
Primary specialty, n (%)  
   Hematologist 312 (92) 
   Oncologist 8 (2) 
   General practitioner 4 (1) 
   Transfusionist 2 (0.6) 
   Cytogeneticist 1 (0.3) 
   Other physician 11 (3) 
Qualification, n (%)  
   Fully qualified 293 (87) 
   In training or completing internship 45 (13) 
Work place, n (%)  
   Teaching hospital 199 (59) 
   General hospital 95 (28) 
   Office-based, cancer center, private hospital or other 44 (13) 
Experience as a physician, mean number of years* 18 
   <16 years’ experience, n (%) 159 (47) 
   ≥16 years’ experience, n (%) 177 (52) 
Mean number of patients with MDS seen per month, n 18 
   As a proportion of total patients seen, % 12 
Mean number of transfusion-dependent patients with MDS 
seen over a 6-month period, n 
19 
*Two (1%) respondents did not answer this question 
 
Detection of iron overload 
On a scale from 1 (not important at all) to 7 (very important), the majority of the respondents 
believed that detection of iron overload in transfusion-dependent patients with MDS was 
‘very important’ (score 7; 46% of respondents) or ‘important’ (score 6; 27%; Fig. 1). The 
mean score for the subjective importance of detecting iron overload in transfusion-dependent 
patients with MDS was 6.1. 
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Fig. 1 Subjective importance of detection of iron overload 
1–2:
Not important
(at all)
3 4 5 6 7:
Very important
2% 5% 20% 27% 46%0%
 
 
On a similar 1–7 scale, most respondents believed that it was ‘very likely’ (score 7; 40%) or 
‘likely’ (score 6; 25%) that iron overload would be detected at their institution (mean score = 
5.8). Approximately half of the respondents (53%) said that they monitored serum ferritin 
levels in their transfusion-dependent patients every 3 months, with 26% responding that the 
frequency of serum ferritin monitoring depended on the rate of transfusions that the patient 
was receiving. Respondents said that in 46% of cases, the results of serum ferritin monitoring 
‘always’ influenced their decisions on how they treated their patients, and ‘sometimes’ 
influenced this in 47% of cases. 
 
The factors that positively influenced detection of iron overload included: patients having 
received >20 RBC units (relevant trigger in 76% of respondents); introduction of serum 
ferritin as a standard test (76%); and awareness of the potential risks of frequent transfusions 
(75%). On a scale from 1 (not an aid at all) to 7 (a strong aid), the mean scores for these 
factors were 6.1, 6.1 and 6.0, respectively. 
 
The most important reasons for not detecting iron overload were poor patient prognosis, 
irregular serum ferritin monitoring, as well as lack of awareness about guidelines and risks of 
iron overload (Fig. 2). Other reasons included a low priority for iron-overload screening, and 
perceptions about the importance of iron overload in MDS. 
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Fig. 2 The most important reservations about the detection of iron overload 
3.7
3.6
3.7
3.8
3.8
4.145
33 41 27
Lack of awareness of guidelines/recommendations 
for proper patient identification
38 32 30Serum ferritin level not regularly monitored
Patient has a poor prognosis and pessimistic life expectancy
Not a barrier (at all)
(score 1–2) Score 3–5
(Strong) barrier
(score 6–7)
Percentage of physicians
Mean of
each barrier
1 2 3 4 5 6 7
37
30
25
41
54
43
23
17
30
0 20 40 60 80 100
Lesser importance of iron overload in the 
context of overall MDS problems
Low priority of iron screening in MDS
Insufficient awareness about the risks of iron overload
in transfusion-dependent patients with MDS
2334
Percentages in each row may not add up to 100% because of rounding  
 
Respondents’ opinions were polarized about whether or not regularly monitoring serum 
ferritin levels was a reason for not detecting iron overload. While 30% said that this ‘strongly 
prevented’ or ‘prevented’ them from detecting iron overload, a similar proportion of 
respondents (38%) believed that this ‘did not’, or ‘did not at all’, prevent them from detecting 
iron overload (Fig. 2). 
 
Treatment of iron overload with iron chelation therapy 
On a scale from 1 (not important at all) to 7 (very important), respondents said that they 
believed that treating iron overload in transfusion-dependent patients with MDS was ‘very 
important’ (score 7; 37% of the respondents) or ‘important’ (score 6; 31%) the mean score 
was 5.9 (Fig. 3). 
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Fig. 3 Subjective importance of treating iron overload 
2% 7% 22% 31% 37%
1:
Not important 
at all
2 3 4 5 6 7: 
Very important
0%
1%  
 
 
The survey showed that 90% of respondents prescribed iron chelation therapy to their 
transfusion-dependent patients with MDS. Nonetheless, not all of these patients received iron 
chelation therapy; out of a mean of 34 transfusion-dependent patients with MDS seen in each 
of the respondents’ practices or institutions in an average 6-month period, 13 (38%) received 
iron chelation therapy. 
 
The factor that most led respondents to initiate iron chelation therapy was patient age of 55–
64 years (relevant trigger in 77% of respondents). On a scale from 1 (does not lead the 
respondent to initiate iron chelation therapy at all) to 7 (strongly leads to initiation of iron 
chelation therapy), the mean score for this factor was 5.9. Other factors that most led 
respondents to initiate iron chelation therapy included: serum ferritin levels >1000 ng/mL 
(76%; mean score 6.0); candidacy for allogeneic stem cell transplantation (76%; mean score 
6.0); need to prevent organ dysfunction (74%; mean score 6.0); ≥2 RBC units transfused per 
month (71%; mean score 5.9); lifetime transfusions of >20 RBC units (68%; mean score 5.8); 
and convenience of oral iron chelation therapy (67%; mean score 5.8). 
 
The majority of respondents who prescribe iron chelation therapy (92%) felt that a patient’s 
serum ferritin reaching a specific level was a marker at which to initiate iron chelation 
therapy. The mean serum ferritin level at which these respondents initiated iron chelation 
therapy was 1130 ng/mL. More than half of the respondents who prescribe iron chelation 
therapy (56%) said that reaching a certain number of blood units transfused was also a 
marker (mean of 21 units). Other markers for initiating iron chelation therapy included: 
patients having received a particular number of transfusions (mean of 18 transfusions; 41% of 
respondents who prescribe iron chelation therapy); and the rate of increase of a patient’s 
serum ferritin level (33% of respondents who prescribe iron chelation therapy). 
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The strongest reasons for not initiating iron chelation therapy were mostly related to poor 
patient prognosis and patient age ≥85 years (Fig. 4). There were polarized opinions regarding 
the importance of some of the reasons for not initiating iron chelation therapy. For example, 
while 31% of respondents replied that a high-risk MDS classification was a strong barrier to 
initiating iron chelation therapy, 25% thought that this did not represent a significant barrier. 
Similarly, while 28% said that expected non-compliance was a strong barrier to initiating iron 
chelation therapy, 23% thought this was a weak barrier. Some of the reasons for not initiating 
iron chelation therapy specifically related to the age of the patients being treated. Older 
patient age was less of a reason to initiate iron chelation therapy, and more of a reason not to, 
than younger patient age. 
 
Fig. 4 The most important reservations about initiating iron chelation therapy. Abbreviations: 
RAEB refractory anemia with excess blasts; CMML chronic myelomonocytic leukemia; WHO 
World Health Organization 
 
4.2
4.1
4.3
4.6
4.7
4.9
5.8
Patient life expectancy is <1 year
Patient is aged ≥85 years
Patient life expectancy is <6 months
Expected non-compliance of the patient
Presence of comorbidity that
would limit prognosis
Health limitation caused by the kidney
High-risk MDS: e.g. High, Int-2 (IPSS) 
or RAEB, CMML (WHO)
Mean of
each barrier
25
23
15
13
15
7
44
49
58
53
44
31
21
31
28
27
34
41
50
72
20
Not a barrier (at all)
(score 1–2) Score 3–5
(Strong) barrier
(score 6–7)
1 2 3 4 5 6 7
Percentage of physicians
0 20 40 60 80 100
Percentages in each row may not add up to 100% because of rounding  
 
Discussion 
This survey was undertaken to better understand what physicians perceive to be the key 
reasons for investigating iron overload and managing iron overload when treating 
transfusion-dependent patients with MDS, and the reasons that they do not. The respondents 
who took part in MIDIS were from multiple European countries, and the majority were 
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experienced physicians who appeared to have a keen interest in the MDS therapy area. Over a 
quarter had more than 25 years’ experience working as physicians and the majority were 
actively involved in the diagnosis and treatment of patients with MDS. The survey has the 
known limitations of optional surveys; i.e., it was performed on invitation at conferences or 
through e-mail alerts and weblinks. Therefore, the survey may have been biased towards 
respondents with an interest in MDS, and who may have had a greater understanding of the 
management of iron overload than the general population of hematologists. Furthermore, 
MIDIS is not a representative sample of the hematologists from each country, and the number 
of respondents from each country does not accurately reflect the proportion of that country’s 
hematologists in Europe. 
 
Nonetheless, the results of the survey provide a valuable insight into the practices and beliefs 
of European physicians treating transfusion-dependent patients with MDS. MIDIS showed 
that approximately 70% of the respondents believed that detecting and treating iron overload 
were important in patients with MDS. A total of 76% of physicians felt that a serum ferritin 
level >1000 ng/mL was a relevant trigger to initiate iron chelation therapy. Over 50% of the 
respondents monitored serum ferritin levels quarterly as a surrogate marker for iron overload 
in their patients and, overall, 38% of transfusion-dependent patients with MDS were actively 
being treated for iron overload with iron chelation therapy. In Europe the prevalence of MDS 
patients with Low/Int-1-risk MDS (according to the IPSS) is reported to be approximately 
70% [2], and 39–50% of those patients are transfusion dependent [13]. Therefore, 
approximately one-third of patients will be transfusion dependent and may be candidates for 
iron chelation therapy, according to published guidelines. The 38% response by the survey 
respondents reflects their active iron chelation treatment strategy. This is confirmed by a 
recent study showing that 41% of eligible patients with lower-risk MDS received iron 
chelation therapy in clinical practice [14]. In all, the views expressed in the survey are in line 
with a number of international guidelines that recommend that serum ferritin levels should be 
assessed 3–4 times per year in transfusion-dependent patients with MDS, and that iron 
chelation therapy should be initiated when their serum ferritin level reaches 1000 ng/mL, 
depending on the transfusion rate [4,15-17]. Interestingly, fewer than a quarter of the 
respondents considered concerns about potential reductions in patient quality of life, the cost 
of iron chelation therapy and possible side effects of therapy as strong reasons for not 
initiating treatment. Only 23%, 19% and 11% of respondents, respectively, reported these as 
barriers or strong barriers to initiating treatment. Furthermore, the issue of potentially reduced 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 12 
quality of life was polarized; the proportion of respondents who considered this to be a 
barrier was similar to the proportion who did not (23% and 26%, respectively). 
 
Participating physicians were asked whether considering iron overload to be a lesser problem 
in patients with MDS was a barrier to detecting iron overload. While 17% thought this was a 
barrier or strong barrier, 30% were strongly opposed to that view. This reflects the need for 
evidence-based data regarding the role of iron chelation in MDS. Serum ferritin is a well-
known acute-phase reactant that might overestimate the iron load in the presence of other 
diseases, in particular infectious episodes [18]. More accurate measurements of iron overload 
include liver and heart magnetic resonance imaging; however, these are time consuming and 
not available at many centers. This may be one reason why one third of MIDIS respondents 
said that they believed that irregular monitoring of serum ferritin levels was a strong barrier 
to detecting iron overload, while 38% thought that this did not prevent detection. 
 
The survey respondents were reluctant to administer iron chelation therapy to patients aged 
≥85 years. It is difficult to assess how transfusion dependence affects the overall survival of 
this elderly patient population with Low- or Int-1-risk MDS. Nonetheless, it is interesting to 
note that the proportion of physicians opting against iron chelation therapy for this population 
was higher than that of physicians opting against treatment for patients with a life expectancy 
of less than one year (Figure 4). Instead, patient age of 55–64 years was a strong reason for 
initiating iron chelation therapy. 
 
In summary, this European survey has demonstrated that physicians believe that iron 
overload is a relevant clinical issue in transfusion-dependent patients with MDS that is 
worthy of investigation and treatment. Concerns over age and patient prognosis are key 
factors in the treatment decisions taken by physicians. An ongoing, randomized Phase III trial 
in patients with Low- and Int-1-risk MDS on iron overload in MDS will help to clarify the 
role of iron chelation therapy in this patient population. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 13 
Acknowledgements 
This study was sponsored by Novartis Farma SpA. Financial support for medical editorial 
assistance was provided by Novartis Farma SpA. We thank Kathy Heptinstall, Didi Jasmin, 
The MDS Foundation and The European School of Haematology for their assistance and 
support with MIDIS and the manuscript. We thank Roy Mazucco for medical editorial 
assistance with this manuscript. 
 
Authors’ contribution 
AG and PF drafted the manuscript. SI analysed the data. AG, DJ, SLdP, SI and PF 
contributed to the study design, data interpretation, and reviewed and provided their 
comments on this manuscript. 
 
Conflict of Interest 
AG reports receiving consultancy and speaker bureau fees, and is a member of the board of 
directors or advisory committee for Novartis Pharma AG, Amgen Inc, GlaxoSmithKline plc, 
Johnson & Johnson Services Inc, and Celgene Corp. DJ is employed by The European School 
of Haematology, which receives unrestricted educational grants from Novartis Pharma AG. 
SLdP is Head of Patient Advocacy of Novartis Oncology Region Europe and has equity in 
Novartis Pharma AG. SI is a full-time employee of GfK SE, the market research agency that 
was commissioned and paid by Novartis Farma SpA to collect and analyze the MIDIS survey 
data. PF reports receiving honoraria and research funding from Celgene Corp, F Hoffmann-
La Roche Ltd, Ortho Biotech Products, Amgen Inc, Cephalon Inc, Merck & Co Inc and 
Novartis Pharma AG. 
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 14 
References 
 
 1.  Hellström-Lindberg E (2005) Management of anemia associated with myelodysplastic 
syndrome. Semin. Hematol. 42:S10-S13 
 2.  Malcovati L, Della Porta MG, Pascutto C, Invernizzi R, Boni M, Travaglino E, 
Passamonti F, Arcaini L, Maffioli M, Bernasconi P, Lazzarino M, Cazzola M (2005) 
Prognostic factors and life expectancy in myelodysplastic syndromes classified 
according to WHO criteria: a basis for clinical decision making. J. Clin. Oncol. 
23:7594-7603 
 3.  Sanz G, Nomdedeu B, Such E, Bernal T, Belkaid M, Ardanaz T, Marco V, Pedro C, 
Ramos F, Consuelo del Cañizo M, Luño E, Cobo F et al (2008) Independent impact of 
iron overload and transfusion dependency on survival and leukemic evolution in 
patients with myelodysplastic syndrome. Blood 112(11):abst 640 
 4.  Bennett JM (2008) Consensus statement on iron overload in myelodysplastic 
syndromes. Am J Hematol 83:858-861 
 5.  Arrizabalaga B, del Cañizo C, Remacha A, Sanz G, Villegas A (2008) Guía clínica de 
quelación del paciente con síndrome mielodisplásico [Clinical guide to chelation 
therapy for patients with myelodysplastic syndrome (Spanish Guidelines)]. 
Haematologica 93(Suppl 1):3-10 
 6.  Santini V, Alessandrino PE, Angelucci E, Barosi G, Billio A, Di MM, Finelli C, 
Locatelli F, Marchetti M, Morra E, Musto P, Visani G et al (2010) Clinical management 
of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk. 
Res.[Epub ahead of print] 
 7.  Bowen D, Culligan D, Jowitt S, Kelsey S, Mufti G, Oscier D, Parker J (2003) 
Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br. J. 
Haematol. 120:187-200 
 8.  National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in 
Oncology v.2: Myelodysplastic Syndromes. 2010. Available at: 
http://www.nccn.org/professionals/physician_gls/pdf/mds.pdf. 
 9.  DeLoughery TG (2009) Iron: The fifth horseman of the apocalypse? Am. J. Hematol. 
84:263-264 
 10.  Tefferi A, Stone RM (2009) Iron chelation therapy in myelodysplastic syndrome - Cui 
bono? Leukemia 23:1373 
 11.  Leukemia Research Fund. Myelodysplastic syndromes: Information and education. 
2010. Available at: http://www.lrf.org.uk/en/1/dismdshome.html. 
 12.  Pullarkat V (2009) Objectives of iron chelation therapy in myelodysplastic syndromes: 
more than meets the eye? Blood 114:5251-5255 
 13.  Brechignac S, Hellstrom-Lindberg E, Bowen DT, DeWitte TM, Cazzola M, Fenaux P 
(2004) Quality of life and economic impact of red blood cell (RBC) transfusions on 
patients with myelodysplastic syndromes (MDS). Blood 104(11):abst 4716 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 15 
 14.  Raptis A, Duh MS, Wang S-T, Dial E, Fanourgiakis I, Fortner B, Paley C, Mody-Patel 
N, Corral M, Scott J (2010) Treatment of transfusional iron overload in patients with 
myelodysplastic syndrome or severe anemia: data from multicenter clinical practices. 
Transfusion 50:190-199 
 15.  Suzuki T, Tomonaga M, Miyazaki Y, Nakao S, Ohyashiki K, Matsumura I, Kohgo Y, 
Niitsu Y, Kojima S, Ozawa K (2008) Japanese epidemiological survey with consensus 
statement on Japanese guidelines for treatment of iron overload in bone marrow failure 
syndromes. Int. J Hematol 88:30-35 
 16.  Wells RA, Leber B, Buckstein R, Lipton JH, Hasegawa W, Grewal K, Yee K, Olney HJ, 
Larratt L, Vickars L, Tinmouth A (2008) Iron overload in myelodysplastic syndromes: 
a Canadian consensus guideline. Leuk Res 32:1338-1353 
 17.  Gattermann N, Porter J, Lopes LF, Seymour J (2005) Consensus statement on iron 
overload in myelodysplastic syndromes. Hematol. Oncol. Clin. North Am 19(Suppl 
1):18-25 
 18.  Jabbour E, Garcia-Manero G, Taher A, Kantarjian HM (2009) Managing iron overload 
in patients with myelodysplastic syndromes with oral deferasirox therapy. Oncologist. 
14:489-496 
 
 
1–2:
Not important
(at all)
3 4 5 6 7:
Very important
2% 5% 20% 27% 46%0%
Figure 1
4.1
3.8
3.8
3.7
3.6
3.7
45
33 41 27
Lack of awareness of guidelines/recommenda ons 
for proper pa ent iden ﬁca on
38 32 30Serum ferri n level not regularly monitored
Pa ent has a poor prognosis and pessimis c life expectancy
Not a barrier (at all)
(score 1–2) Score 3–5
(Strong) barrier
(score 6–7)
Percentage of physicians
Mean of
each barrier
1 2 3 4 5 6 7
37
30
25
41
54
43
23
17
30
0 20 40 60 80 100
Lesser importance of iron overload in the 
context of overall MDS problems
Low priority of iron screening in MDS
Insuﬃcient awareness about the risks of iron overload
in transfusion-dependent pa ents with MDS
2334
Percentages in each row may not add up to 100% because of rounding
Figure 2
2% 7% 22% 31% 37%
1:
Not important 
at all
2 3 4 5 6 7: 
Very important
0%
1%
Figure 3
5.8
4.9
4.7
4.6
4.3
4.2
4.1
Paent life expectancy is <1 year
Paent is aged ≥85 years
Paent life expectancy is <6 months
Expected non-compliance of the paent
Presence of comorbidity that
would limit prognosis
Health limitaon caused by the kidney
High-risk MDS: e.g. High, Int-2 (IPSS) 
or RAEB, CMML (WHO)
Mean of
each barrier
25
23
15
13
15
7
44
49
58
53
44
31
21
31
28
27
34
41
50
72
20
Not a barrier (at all)
(score 1–2) Score 3–5
(Strong) barrier
(score 6–7)
1 2 3 4 5 6 7
Percentage of physicians
0 20 40 60 80 100
Percentages in each row may not add up to 100% because of rounding
Figure 4
Table 1 Countries represented in the survey 
Country Responses Country Responses 
Austria 8 Macedonia 6 
Belgium 22 Malta 1 
Bulgaria 4 Netherlands 2 
Croatia 4 Norway 2 
Czech Republic 19 Poland 11 
Denmark 5 Portugal 9 
Estonia 4 Romania 6 
Finland 1 Serbia 1 
France 43 Slovakia 19 
Germany 20 Spain 45 
Greece 16 Sweden 4 
Hungary 3 Switzerland 7 
Italy 39 UK 36 
Lithuania 1   
Total number of responses  338 
 
Table
Table 2 Respondent characteristics 
Characteristic n = 338 
Mean age, years 44 
Male : female, n (%) 183 (54) : 155 (46) 
Primary specialty, n (%)  
   Hematologist 312 (92) 
   Oncologist 8 (2) 
   General practitioner 4 (1) 
   Transfusionist 2 (0.6) 
   Cytogeneticist 1 (0.3) 
   Other physician 11 (3) 
Qualification, n (%)  
   Fully qualified 293 (87) 
   In training or completing internship 45 (13) 
Work place, n (%)  
   Teaching hospital 199 (59) 
   General hospital 95 (28) 
   Office-based, cancer center, private hospital or other 44 (13) 
Experience as a physician, mean number of years* 18 
   <16 years’ experience, n (%) 159 (47) 
   ≥16 years’ experience, n (%) 177 (52) 
Mean number of patients with MDS seen per month, n 18 
   As a proportion of total patients seen, % 12 
Mean number of transfusion-dependent patients with MDS 
seen over a 6-month period, n 
19 
*Two (1%) respondents did not answer this question 
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